Anti Infective Drugs Market : Facts, Figures and Analytical Insights 2020-2026

Global Anti-Infective Drugs Market was valued at USD 84.07 Billion in 2018 and is projected to reach USD 141.8 Billion by 2026, growing at a CAGR of 6.7% from 2019 to 2026.

The Anti Infective Drugs Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the impact of COVID-19 (Corona Virus) on the product industry chain based on the upstream and downstream markets, on various regions and major countries and on the future development of the industry are pointed out.

Click the link to get a Sample Copy of the Report:
https://www.marketinsightsreports.com/reports/08262257164/global-anti-infective-drugs-market/inquiry?source=openpr&Mode=12

The 197 report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Anti Infective Drugs Market: Novartis, Merck & Co., Johnson & Johnson, GlaxoSmithKline plc, Gilead Sciences, Boehringer Ingelheim GmbH, Pfizer, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd.

Basel, Switzerland, October 3, 2018 - Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis Infectious Diseases portfolio, which have the potential to address the need for new agents to treat antibiotic resistant Gram-negative infections. Antibiotic resistance is widely recognized as a major public health threat and innovative candidates to combat drug resistant bacteria remain a critical unmet need. Both the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) have identified CRE and drug resistant Pseudomonads as serious threats that pose significant risk to human health.

"The need for new antibiotics that address drug resistant bacteria is clear and we are pleased to find a partner in Boston Pharmaceuticals who will dedicate the appropriate expertise and resources for the further development and commercialization of these programs," said Jay Bradner, M.D., President of the Novartis Institutes for BioMedical Research. "Drug discovery and development is a team sport and this agreement is part of our strategy to partner with like -minded innovators outside of our walls to further develop new innovative medicines focused on addressing global health challenges."

28 October 2019: GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin

London, UK: GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase III clinical programme investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (uUTI, also known as acute cystitis) and urogenital gonorrhoea (GC). Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK said: “Given the increasing rate of antibiotic drug resistance, and gepotidacin’s unique mechanism of action, we believe this drug has the potential to transform the treatment landscape for patients with uncomplicated urinary tract infection and urogenital gonorrhoea who currently have limited therapeutic options.” The phase III programme, comprising two studies, will test gepotidacin in two common infections caused by bacteria identified as antibiotic resistant threats by the Centers for Disease Control and Prevention, a division of the US Department of Health and Human Services.

Key Market Trends

The growing burden of several infectious diseases across the developed and emerging markets such as different types of influenza, diarrhea, hepatitis, and urinary tract infections, that requires the more attention from pharmaceutical and biotechnological companies. This, in turn, the primary factor for the growth of the global anti-infective drug market. The development of new multi-drug resistance against micro-organisms is another factor further expected to fuel the growth of the market. However, high investment costs in research and development and shortage of resources in healthcare facilities are the factors that might restrict the market growth.

Influence Of The Anti Infective Drugs Market Report:

-Comprehensive assessment of all opportunities and risk in the Anti Infective Drugs market.
- Anti Infective Drugs market recent innovations and major events.
-A detailed study of business strategies for growth of the Anti Infective Drugs market-leading players.
-Conclusive study about the growth plot of Anti Infective Drugs market for forthcoming years.
-In-depth understanding of Anti Infective Drugs market-particular drivers, constraints and major micro markets.
-Favourable impression inside vital technological and market latest trends striking the Anti Infective Drugs market.

Buy The Report:
https://www.marketinsightsreports.com/report/purchase/08262257164?mode=su?source=openpr&Mode=12

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on regional scale.

Analytical Tools: The Anti Infective Drugs Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

The report has 150 tables and figures browse the report description and TOC:
https://www.marketinsightsreports.com/reports/08262257164/global-anti-infective-drugs-market?source=openpr&Mode=12

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.
Please connect with our sales team (sales@marketinsightsreports.com).

Contact Us:
Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.